MC2 Therapeutics is a commercial stage pharmaceutical company engaged in development of novel treatment paradigms for people with immune-mediated conditions with an initial focus on manifestations in the skin. Our innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology – and this knowledge can be leveraged to inform approaches in other disease segments in the immune-mediated and inflammatory field. Fuelled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with immune-mediated and inflammatory skin conditions. This page is not intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about MC2 Therapeutics and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Please keep in mind that MC2 Therapeutics work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of MC2 Therapeutics.
